Karen Knudsen is leading Sean Parker’s cancer immunotherapy incubator where philanthropy and venture capital meet.

The material is a construction-ready alternative that meets industry standards and outperforms traditional methods.

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

Scientists and doctors remain divided on the targeted antibody drugs that slow down the early stages of Alzheimer’s ...

In an unprecedented scientific feat, researchers have bridged the gap between humans and humpback whales, achieving a ...

News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /CNW/ — News Commentary – With analysts forecasting the global oncology ...

An international research team has achieved a significant breakthrough in research into the reproduction of dogrose. The ...

Genomic research holds incredible promise for improving human health, but one major challenge has slowed its progress: ...

Hours of talks aimed at de-escalating fighting between Israel and Iran failed to produce a diplomatic breakthrough as the war ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Following their breakthrough horror series From, MGM+ has unveiled the first trailer for The Institute, the upcoming Stephen King adaptation.

Recently, Knudsen assumed the CEO post at the Parker Institute for Cancer Immunotherapy — created by Sean Parker, Facebook's first president and the tech entrepreneur behind breakthrough ideas ...